Literature DB >> 29804393

[Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update].

.   

Abstract

Entities:  

Keywords:  Diagnosis; Fatty liver; Guidebooks; Metabolic syndrome; Therapy

Year:  2018        PMID： 29804393     DOI： 10.3760/cma.j.issn.1007-3418.2018.03.008

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN： 1007-3418


× No keyword cloud information.
  27 in total

1.  Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease.

Authors:  Yuqing Zhou; Wen Lu; Guorong Yang; Yifeng Chen; Jiwei Cao; Chunli Zhou
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Association between the LRP5 rs556442 gene polymorphism and the risks of NAFLD and CHD in a Chinese Han population.

Authors:  Dongli Han; Haiying Zhang; Shousheng Liu; Likun Zhuang; Zhenzhen Zhao; Hongguang Ding; Yongning Xin
Journal:  BMC Gastroenterol       Date:  2022-06-22       Impact factor: 2.847

3.  Influences of Vitamin D Levels and Vitamin D-Binding Protein Polymorphisms on Nonalcoholic Fatty Liver Disease Risk in a Chinese Population.

Authors:  Min Wang; Minxian Wang; Ru Zhang; Chao Shen; Liuxin Zhang; Yajie Ding; Zongzhe Tang; Hongliang Wang; Wei Zhang; Yue Chen; Jie Wang
Journal:  Ann Nutr Metab       Date:  2022-01-31       Impact factor: 5.923

4.  Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis.

Authors:  Hong-Lei Ma; Kenneth I Zheng; Rafael S Rios; Liang-Jie Tang; Gang Li; Pei-Wu Zhu; Xiao-Dong Wang; Yong-Ping Chen; Ming-Hua Zheng
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

5.  Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.

Authors:  Li-Zhen Chen; Hong-Yun Ding; Shou-Sheng Liu; Qun Liu; Xiang-Jun Jiang; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Lipids Health Dis       Date:  2019-02-09       Impact factor: 3.876

6.  Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.

Authors:  Ying Luo; Pijian Yang; Zhengming Li; Yunchen Luo; Jing Shen; Ruwen Li; Hua Zheng; Yuzhen Liang; Ning Xia
Journal:  Drug Des Devel Ther       Date:  2019-12-02       Impact factor: 4.162

7.  A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test.

Authors:  Xiaoyu Hou; Yunpeng Guan; Yong Tang; An Song; Jiajun Zhao; Luping Ren; Shuchun Chen; Limin Wei; Huijuan Ma; Guangyao Song
Journal:  Lipids Health Dis       Date:  2021-05-25       Impact factor: 3.876

8.  Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice.

Authors:  Wen-Cong Li; Su-Xian Zhao; Wei-Guang Ren; Yu-Guo Zhang; Rong-Qi Wang; Ling-Bo Kong; Qing-Shan Zhang; Yue-Min Nan
Journal:  Exp Ther Med       Date:  2021-06-03       Impact factor: 2.447

Review 9.  Regulation of Mitochondrial Function by Natural Products for the Treatment of Metabolic Associated Fatty Liver Disease.

Authors:  Tingting Shi; Liping Yu; Rangxiao Zhuang; Jianjun Xi; Ruoyu He; Yidan Shao; Jinsong Huang; Shourong Liu; Xingxin Yang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-06-16

10.  High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes.

Authors:  Ying Tan; Xixiang Tang; Panwei Mu; Yi Yang; Mei Li; Yuanpeng Nie; Haicheng Li; Yanhua Zhu; Yanming Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-22       Impact factor: 3.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.